LifeMD, Inc. (LFMD) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerns: a decline in weight management revenue, reduced financial guidance, and margin pressures due to shifts in business mix. Although there is optimism for 2026 and some positive developments like insurance coverage and new product lines, these are long-term prospects. The immediate financial outlook is weakened by the revised guidance and margin erosion, leading to a likely negative market reaction in the short term.
Key Financial Performance
Telehealth Revenue $47.3 million, an 18% increase year-over-year. The growth was attributed to strong subscriber growth and increased demand for telehealth services.
Consolidated Revenue $60.2 million, a 13% increase year-over-year. The increase was driven by the growth in telehealth revenue and overall business expansion.
Telehealth Adjusted EBITDA $2.9 million, a 30% increase year-over-year. This improvement was due to operational efficiencies and revenue growth.
Gross Margin 88%, a decline of 290 basis points year-over-year. The decline was due to changes in revenue mix.
Gross Profit $52.8 million, a 9% increase year-over-year. The increase was driven by higher revenue despite a slight decline in gross margin.
Telehealth Subscriber Growth 310,000 active subscribers, a 14% increase year-over-year. The growth was driven by strong demand for telehealth services.
GAAP Net Loss $4.6 million, compared to $5.4 million in the prior year. The reduction in loss was due to improved operational performance and revenue growth.
Adjusted EBITDA $5.1 million, compared to $4.3 million in the prior year. The increase was due to improved operational efficiencies and revenue growth.
Cash Position $23.8 million with no debt, marking the strongest balance sheet in the company's history. This was achieved through the divestiture of WorkSimpli and debt payoff.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Women's health and behavioral health offerings: Substantial progress made, with potential to become 9-figure businesses over the next 3 years.
LifeMD+ membership and in-app health marketplace: Advanced development to enhance patient experience, engagement, and retention.
Nonsterile 503-A compounding pharmacy: Secured regulatory approval, enabling production of personalized medications at scale with improved economics.
RexMD personalized ED medications: Exceptional demand, representing 25% of all new ED prescriptions on the platform.
Hormone replacement therapy (HRT): Strong momentum with expansion into 35 states for men's HRT.
Weight management offering: Stabilized and positioned for significant growth in 2026, leveraging collaborations with Novo Nordisk and Eli Lilly.
GLP-1 therapies: LifeMD to offer Wegovy and Ozempic at reduced prices, with expected approval of Wegovy pill and Eli Lilly's oral GLP-1 in 2026.
Women's health and behavioral health: Strong demand with plans to invest in growth early in 2026.
Telehealth revenue: Increased 18% year-over-year to $47.3 million.
Adjusted EBITDA: Grew 30% year-over-year to $2.9 million.
Gross margin: Maintained at 88%, despite a slight decline due to revenue mix.
Active subscribers: Increased 14% year-over-year to over 310,000.
Divestiture of WorkSimpli: Strengthened balance sheet and allowed focus on core virtual care and pharmacy business.
Insurance enablement: Remains a top strategic priority for 2026 to enhance patient access and retention.
Integrated virtual care marketplace: Investing in a unified platform to improve patient experience and expand service offerings.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Weight Management Competition: Intense competition from low-cost and low-quality compounded GLP-1 makers has created near-term pressure on the weight management category. These competitors offer prices that LifeMD cannot match, leading to challenges in maintaining market share.
Regulatory and Pricing Challenges: The company faces challenges in navigating regulatory approvals and pricing strategies for new products, such as the Wegovy pill and other GLP-1 therapies. Delays or pricing missteps could impact market adoption and profitability.
Insurance Enablement Delays: The slower-than-expected deployment of insurance enablement on the platform could hinder patient access and retention, impacting revenue growth in key verticals like women's health and behavioral health.
Revenue Mix Impact on Margins: A shift in revenue mix has led to a decline in gross margins, which could affect overall profitability if not managed effectively.
Operational Risks in Pharmacy Transition: The planned transition of ED medication fulfillment to LifeMD's in-house pharmacy in early 2026 carries operational risks, including potential disruptions and cost overruns.
Scaling New Verticals: The company is investing heavily in new verticals like women's health and behavioral health, which are not yet contributing meaningfully to revenue. There is a risk that these investments may not yield the expected returns.
Economic Pressures on Consumer Spending: Economic uncertainties and pressures on consumer spending could impact the adoption of LifeMD's services, particularly in discretionary categories like weight management and men's health.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Weight Management Offering: LifeMD plans to accelerate growth in its weight management offering by leveraging collaborations with Novo Nordisk and Eli Lilly. The company expects significant growth in 2026, supported by price reductions for branded GLP-1 therapies and the anticipated approval of oral Wegovy and orforglipron in 2026.
Women's and Behavioral Health Businesses: LifeMD aims to scale its virtual women's and behavioral health businesses, which are expected to become significant revenue contributors in 2026. The company plans to invest in these verticals to rapidly build the patient base and drive long-term retention.
RexMD Expansion: LifeMD plans to expand RexMD by introducing personalized compounded medications and hormone therapies. The company will transition fulfillment of ED medications to its in-house pharmacy in early 2026, reducing costs and improving margins.
LifeMD Platform Enhancements: The company is investing in a unified LifeMD platform and marketplace to improve patient engagement and cross-care participation. Upgrades, including a relaunch of the website and mobile app, are expected to roll out by early Q1 2026.
Telehealth Revenue and Subscriber Growth: LifeMD expects telehealth revenue to grow 18% year-over-year in 2025, with active subscribers increasing 14% to over 310,000 by the end of Q3 2025.
Financial Guidance for 2025: LifeMD projects full-year 2025 revenue of $192 million to $193 million, representing 24% growth, and adjusted EBITDA of $13.5 million to $14.5 million, a 254% increase compared to 2024.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the mix of telehealth product revenue, especially in weight loss, and the reasons for the sequential decline?
A:Weight management accounts for more than 50% of the company's total revenue mix. There was a slight sequential decline in revenue, with the subscriber base down by about 1,000 quarter-on-quarter but now stabilized. More than half of new patient sign-ups are coming through branded therapy, though it represents less than half of total revenue. The decline was partly due to the loss of fulfillment fees from personalized compounds, which had a $50 impact per order. The company expects growth to return in 2026 with product innovations.
Q:What are the expectations for the weight management business in 2026?
A:The company expects better pricing for branded therapies and increased payer coverage, including Medicare. They are optimistic about FDA cracking down on compounding, which would benefit their business. They anticipate solid growth driven by these factors.
Q:Are the majority of new obesity health members on branded products?
A:Yes, the majority of new patients are on branded products. Currently, the percentage is at the lower end of the 50%-75% range but is expected to increase as prices for branded therapies decrease to $200-$300 per month.
Q:What portion of revenue is currently insurance-covered versus cash pay, and what is the expectation for 2026?
A:The company is not prepared to provide exact numbers for 2026. However, they are ready to capitalize on Medicare coverage for these drugs, which is expected to significantly impact revenue. Currently, about 25% of patients do not continue with the program due to lack of insurance coverage. The company has seen a 33% reduction in customer acquisition costs after enabling insurance coverage for some patients.
Q:What is the value LifeMD brings to members compared to competitors like Amazon or Costco?
A:LifeMD differentiates itself by offering a portfolio of services, including state-licensed provider visits, preventative care, lab work, hormone health, and a cardiovascular program. They also have a compounding pharmacy for other medications. Unlike Costco, LifeMD provides access to providers who can write prescriptions. The brand and comprehensive care offerings set them apart from competitors.
Q:Was there any revenue impact from the revision?
A:The revision had a $1.1 million impact on this year, but there was no impact on the current quarter's results.
Q:Has the brand uptake been diluted by Novo Nordisk's other partnership deals?
A:The company does not believe Novo Nordisk's other partnerships have impacted demand on their platform. The main challenge is the competitive pricing of compounded therapies, which are often significantly cheaper than branded therapies. The company is optimistic about branded therapy demand but emphasizes the need for better pricing and coverage.
Q:What is driving the return to RexMD growth, and how does the telehealth gross margin outlook appear?
A:Most of the growth (8,000 out of 10,000) came from the ED business, with the rest from HRT, hair loss, and insomnia. Telehealth gross margins declined due to a shift to branded products in weight management and a change in business mix. Future margins may slightly erode due to new offerings in women's and behavioral health and the scaling of the 503-A compounding pharmacy.
Q:What observations have been made after turning on insurance broadly, and how will the new app impact cross-selling?
A:Turning on insurance broadly led to a 33% reduction in customer acquisition costs, indicating strong demand for insurance-covered services. The new app is expected to significantly enhance cross-selling, potentially adding 50-100 consults per day and improving customer retention and lifetime value.
Q:What is the timeline for 503-A pharmacy licensing in all states, and what margin impact is expected?
A:The company expects to be licensed in 35 states within 60-90 days and in all 50 states within a few months, except for a few difficult states like California. Owning a 503-A pharmacy is expected to significantly improve margins by reducing costs and enhancing the patient experience.
Q:What is the expected impact of oral obesity products on the market?
A:The company anticipates significant demand for oral obesity products, potentially expanding the market by 25%-50%. They believe these products will attract patients who avoid injectables.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers for the percentage of revenue expected to be insurance-related by the end of 2026. They also did not provide precise figures for the percentage of new obesity health members on branded products in the last 30 days, stating only that it is at the lower end of the 50%-75% range. Additionally, they did not quantify the exact impact of oral obesity products on the market, acknowledging the difficulty in estimating demand.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Americans treatment
Analysts
Benathen
Demand
Eli Lilly
FDA
RexMD
addition
app
approval
balance sheet
care patient
care pharmacy
care provider
carte
compounding pharmacy
decision
dermatology
destination
dos
dose
formulation
functionality
health business
house
offering vertical
partner majority
party pharmacy
pay patient
pharmacy partner
pill
platform priority
price
psychiatry
quality weight
reduction
resource core
term retention
today result
weight offering
LFMD Transcript
LifeMD, Inc. (LFMD) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call reveals a mixed picture: increased losses and a decline in revenue, yet strong cash position and strategic partnerships with Novo and Lilly. The Q&A highlights promising insurance-supported programs and strategic shifts, but concerns about revenue guidance and unclear management responses persist. With no market cap data, the lack of strong catalysts and mixed financial indicators suggest a neutral stock price movement in the short term.
LifeMD, Inc. (LFMD) Q4 2025 Earnings Call Transcript
Positive3-9
The earnings call highlights strong financial performance with revenue and EBITDA growth, no debt, and a positive cash position. The Q&A reveals robust demand for the Wegovy pill, promising initial retention rates, and strategic investments in growth areas like women's health. While management was vague on some specifics, the overall sentiment remains positive due to strong financial metrics, optimistic guidance, and strategic partnerships, despite some uncertainties.
LifeMD, Inc. (LFMD) Q3 2025 Earnings Call Transcript
Unknown11-17
The earnings call reveals several concerns: a decline in weight management revenue, reduced financial guidance, and margin pressures due to shifts in business mix. Although there is optimism for 2026 and some positive developments like insurance coverage and new product lines, these are long-term prospects. The immediate financial outlook is weakened by the revised guidance and margin erosion, leading to a likely negative market reaction in the short term.
LifeMD, Inc. (LFMD) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call presents mixed signals: strong telehealth revenue growth and strategic partnerships are positive, but concerns arise from fluctuating customer acquisition costs and guidance reduction related to the RexMD business. The Q&A reveals management's evasiveness on certain metrics, which can create uncertainty. Despite positive new initiatives and raised guidance for 2025, the immediate impact is tempered by operational challenges and lack of clear answers on key metrics, resulting in a neutral sentiment.
LFMD Slides
LFMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
